Costs of treatment change following first-line somatostatin analog monotherapy among patients with neuroendocrine tumors.

Higher total healthcare costs were observed following treatment change from first-line SSA. Switching to the alternate SSA was associated with a fixed, one-time cost; whereas, switching to targeted therapy was associated with both an initial switching cost and a persistent monthly increase.